Synaptic Dysfunction and Energy Failure in Parkinson's Disease

帕金森病的突触功能障碍和能量衰竭

基本信息

  • 批准号:
    10504365
  • 负责人:
  • 金额:
    $ 42.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-15 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Summary Parkinson’s disease (PD) is the second most common neurodegenerative disease. Loss of substantia nigra compacta (SNc) dopaminergic projections and decreased striatal dopamine levels are the characteristic features of PD. Emerging evidence suggest that synaptic dysfunction of dopamine neurons is an early event in the pathogenesis of PD occurring prior to the onset of symptoms. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most prevalent causes of familial and sporadic PD, demonstrating an unprecedented significant role in PD pathogenesis. A transgenic mouse model with over-expression of human LRRK2- R1441G has been shown to recapitulate robust motor behavioral, neurochemical and pathological features of PD. At the level of pathology, the most robust phenotype is the axonopathy of the nigrostriatal dopaminergic projection, accompanied by age-dependent hyperphosphorylated tau and DA transmission deficits. Both genetic and environmental causes of PD have highlighted the importance of mitochondrial dysfunction in the pathogenesis of PD. Mitochondrial trafficking is critical for neurons’ survival and functions including synaptic neurotransmission. However, mitochondrial trafficking and dynamics in mutant LRRK2 associated-PD has not been well studied. We find that the mitochondrial oxidant stress is elevated in the LRRK2-R1441G mutants whereas mitochondrial respiration and mitochondrial ATP synthesis is significantly reduced. In addition, our preliminary studies uncovered early and defining features in mitochondria trafficking and dynamics impairment: frangmented mitochondria in SNc dopamine neurons and terminals, increased cytosolic calcum levels, tau hyperphosphorylation, and decreased anterograde healthy mitochondrial transport. We hypothesize that R1441G mutation impairs mitochondria trafficking and dynamics via dysregulation of Miro1 and calcium homeostasis and pathologic tau accumulation that ultimately result in synaptic dysfunction, energy failure and axonal degeneration. We will utilize a combination of two-photon imaging (2PLSM) and electrophysiology recording in living brain slices, and mouse genetics to uncover mechanisms underlying DAergic transmission deficits and axonal degeneration in PD.
概括 帕金森病(PD)是第二常见的神经退行性疾病。损失 黑质致密区 (SNc) 多巴胺能投射和纹状体多巴胺减少 水平是PD的特征。新出现的证据表明突触 多巴胺神经元功能障碍是 PD 发病机制中的一个早期事件,发生在 PD 之前。 症状出现。富含亮氨酸重复激酶 2 (LRRK2) 基因的突变是 家族性和散发性帕金森病最常见的病因,显示出前所未有的显着性 在 PD 发病机制中的作用。人类 LRRK2 过度表达的转基因小鼠模型 R1441G 已被证明能够重现强大的运动行为、神经化学和 PD的病理特征。在病理学水平上,最稳健的表型是 黑质纹状体多巴胺能投射的轴突病,伴有年龄依赖性 过度磷酸化的 tau 蛋白和 DA 传输缺陷。遗传和环境原因都有 PD 的研究强调了线粒体功能障碍在 PD 发病机制中的重要性。 线粒体运输对于神经元的生存和功能(包括突触)至关重要 神经传递。然而,突变体 LRRK2 中的线粒体运输和动力学 相关PD尚未得到充分研究。我们发现线粒体氧化应激是 LRRK2-R1441G 突变体中线粒体呼吸和线粒体呼吸作用升高 ATP 合成显着减少。此外,我们的初步研究发现早期和 线粒体运输和动力学损伤的定义特征:支离破碎 SNc 多巴胺神经元和末梢中的线粒体、胞浆钙水平、tau 蛋白增加 过度磷酸化,并减少顺行健康线粒体运输。我们 假设 R1441G 突变通过以下方式损害线粒体运输和动力学 Miro1 和钙稳态的失调以及病理性 tau 积累最终导致 导致突触功能障碍、能量衰竭和轴突变性。我们将利用一个 双光子成像 (2PLSM) 和活体大脑电生理学记录的结合 切片和小鼠遗传学揭示 DAergic 传输缺陷的机制 和 PD 中的轴突变性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HUI ZHANG其他文献

HUI ZHANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HUI ZHANG', 18)}}的其他基金

Synaptic Dysfunction and Energy Failure in Parkinson's Disease
帕金森病的突触功能障碍和能量衰竭
  • 批准号:
    10891269
  • 财政年份:
    2022
  • 资助金额:
    $ 42.91万
  • 项目类别:
Regulation of SOX Proteins by Methylation-dependent Proteolysis in Stem Cells and Development
干细胞和发育中甲基化依赖性蛋白水解对 SOX 蛋白的调节
  • 批准号:
    10531566
  • 财政年份:
    2020
  • 资助金额:
    $ 42.91万
  • 项目类别:
Regulation of SOX Proteins by Methylation-dependent Proteolysis in Stem Cells and Development
干细胞和发育中甲基化依赖性蛋白水解对 SOX 蛋白的调节
  • 批准号:
    10308399
  • 财政年份:
    2020
  • 资助金额:
    $ 42.91万
  • 项目类别:
Supplement: Regulation of SOX Proteins by Methylation-dependent Proteolysis in Stem Cells and Development
补充:干细胞和发育中甲基化依赖性蛋白水解作用对 SOX 蛋白的调节
  • 批准号:
    10810083
  • 财政年份:
    2020
  • 资助金额:
    $ 42.91万
  • 项目类别:
Elucidating Aberrant Dopamine Release in Schizophrenia
阐明精神分裂症中多巴胺的异常释放
  • 批准号:
    7871680
  • 财政年份:
    2010
  • 资助金额:
    $ 42.91万
  • 项目类别:
Elucidating Aberrant Dopamine Release in Schizophrenia
阐明精神分裂症中多巴胺的异常释放
  • 批准号:
    8055400
  • 财政年份:
    2010
  • 资助金额:
    $ 42.91万
  • 项目类别:
Regulation of Replication Checkpoint by Proteolysis
蛋白水解调节复制检查点
  • 批准号:
    7483524
  • 财政年份:
    2004
  • 资助金额:
    $ 42.91万
  • 项目类别:
Regulation of Replication Checkpoint by Proteolysis
蛋白水解调节复制检查点
  • 批准号:
    7066587
  • 财政年份:
    2004
  • 资助金额:
    $ 42.91万
  • 项目类别:
Regulation of Replication Checkpoint by Proteolysis
蛋白水解调节复制检查点
  • 批准号:
    7236706
  • 财政年份:
    2004
  • 资助金额:
    $ 42.91万
  • 项目类别:
Regulation of Replication Checkpoint by Proteolysis
蛋白水解调节复制检查点
  • 批准号:
    6777947
  • 财政年份:
    2004
  • 资助金额:
    $ 42.91万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.91万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了